The Spero Project, a local resettlement agency, will host a walk at Scissortail Park to raise money to help refugees in t ...

In the last week, the market has been flat, but over the past 12 months, it has risen by 12%, with earnings forecast to grow by 14% annually. While traditional investments often focus on established ...

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock soar by 240% after announcing highly encouraging results from its Phase ...

These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Spero Therapeutics, ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US ...

GSK and Spero Therapeutics announced that a Phase 3 trial for their complicated UTI antibiotic reached its primary endpoint, ...

May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics (SPRO), Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr ...